Join the #FierceMadness!
Pick your favorite drug names in this year's tournament challenge. Read more and vote here!
Gilead released data from a clinical trial showing that its new three-med HIV combo Biktarvy is noninferior to a treatment containing three GSK drugs.
“Corruption cannot be allowed to become a tradition,” one shareholder told Novartis brass amid a bribery scandal under investigation in Greece.
Clinical care experts and patient advocacy organizations call attention to why better patient understanding shapes the best integrated approach to orphan drug…
After Lilly CEO David Ricks took over in 2016, he revamped management while cutting costs and jobs—and earned nearly $16 million in pay for his efforts.
Bayer CEO Werner Baumann admitted the company isn't doing enough to keep up with U.S. consumers' rapid shift toward buying health products online.
Facing tough competition for Tecentriq in bladder cancer, Roche plans to test the drug in combination with Tesaro's PARP inhibitor Zejula.
Members of an anarchist group smashed windows and hurled red paint at Novartis' Greece office, as the drugmaker faces kickback probe.
Gilead's executive v.p. of worldwide commercial operations is unexpectedly retiring, at a time when the company is facing challenges across its infectious…
Merck’s Kenneth Frazier is breaking his silence about his decision last August to resign from the president's manufacturing council.
With an early approval for its new drug Erleada, J&J just got a head start over Pfizer and Astellas in nonmetastatic prostate cancer.
Former Celgene chief Bob Hugin is confirming his candidacy for the U.S. Senate Tuesday, in an announcement that's generating both optimism and scorn.